Proteomic Profiling Identifies CLDN3 as a Tumor-Selective Therapeutic Target in Small Cell Lung Cancer
Schroeder, B. A.; Choi, J.; Schaffer, A. A.; Nirula, M.; Cao, Y.; Zhang, Y.; Meinhardt, A.-L.; Kwon, H.; Park, H.; Lee, S.; Shin, H. J.; Park, H. G.; Yang, H.; Hong, S.; Desai, P.; Butcher, D.; Sukprasert, P.; Wang, B.; Biery, D. N.; El Meskini, R.; Atkinson, D.; Bassel, L. L.; Weaver Ohler, Z.; Huang, Y.; Hunt, A. L.; Abulez, T.; Bateman, N. W.; Conrads, T. P.; Lake, R.; Hewitt, S. M.; Hong, S.; Kim, J.; Jung, S. H.; Lee, H. J.; Lee, S.; Shin, Y. K.; Ruppin, E.; Thomas, A.
Show abstract
Small cell lung cancer (SCLC) remains a highly lethal disease with limited targetable surface antigens beyond delta-like ligand 3 (DLL3). We sought to systematically identify and validate tumor-selective cell-surface targets in relapsed SCLC. To this end, we developed an integrated proteogenomic pipeline combining single-cell RNA sequencing, combinatorial optimization, mass spectrometry-based proteomics, and immunohistochemistry to systematically map the SCLC surfaceome of 49 tumors across 25 patients with relapsed SCLC. Using this approach we found claudin-3 (CLDN3) to be a consistently expressed and tumor-selective antigen, with broader coverage than DLL3, which is the current clinical benchmark. CLDN3 was highly expressed across various treatment states, while maintaining low expression in most nonmalignant tissues. Functional validation using a novel CLDN3-specific monoclonal antibody (ABN501) demonstrated NK cell-mediated cytotoxicity in vitro and tumor regression in vivo, as well as a favorable safety profile. These findings support clinical development of CLDN3-directed therapies and demonstrate the utility of integrated proteogenomic approaches for antigen discovery in solid tumors.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A focal adhesion kinase-YAP signaling axis drives drug tolerant persister cells and residual disease in lung cancer 95%
- Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers 95%
- Whole genome sequencing improves tissue of origin diagnosis and treatment options for cancer of unknown primary 94%
Similar papers in this journal
- Generation of a biliary tract cancer cell line atlas reveals molecular subtypes and therapeutic targets 95%
- Multimodal Spatial Profiling Reveals Immune Suppression and Microenvironment Remodeling in Fallopian Tube Precursors to High-Grade Serous Ovarian Carcinoma 94%
- Deep Learning Model for Tumor Type Prediction using Targeted Clinical Genomic Sequencing Data 93%
Similar papers in this journal
Similar papers in this journal
- ETS1 Orchestrates a Hybrid EMT Program Driving in vivo Metastasis and Immune Evasion 93%
- Combinatorial tumor suppressor inactivation efficiently initiates lung adenocarcinoma with therapeutic vulnerabilities 93%
- EZH2 synergizes with BRD4-NUT to drive NUT carcinoma growth through silencing of key tumor suppressor genes 93%
Similar papers in this journal
- Combined KRASG12C and SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistance 94%
- Glutamine mimicry suppresses tumor progression through asparagine metabolism in pancreatic ductal adenocarcinoma 94%
- Cancer-associated fibroblast compositions change with breast cancer progression linking S100A4 and PDPN ratios with clinical outcome 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.